Surgical Strategies for Bismuth Type I and II Hilar Cholangiocarcinoma: Impact on Long-Term Outcomes. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract Zhang, X., Zhang, N., Tsilimigras, D. I., Weber, S. M., Poultsides, G., Hatzaras, I., Fields, R. C., He, J., Scoggins, C., Idrees, K., Shen, P., Maithel, S. K., Pawlik, T. M. 2021

Abstract

BACKGROUND: The surgical approach to treat Bismuth type I and II hilar cholangiocarcinoma (HCCA) has been a topic of debate. We sought to characterize whether bile duct resection (BDR) with or without concomitant hepatic resection (HR) was associated with R0 margin status, as well asdefine the impact of HR+BDR versus BDR alone on long-term survival.METHODS: Patients who underwent curative-intent HR+BDR for HCCA between 2000 and 2014 were identified from a multi-institutional database. Perioperative and long-term outcomes were compared among patients who underwent BDR only, BDR+left hepatic resection (LHR), and BDR+right hepatic resection (RHR) for Bismuth type I and II HCCA.RESULTS: Among 257 patients with HCCA, 61 (23.7%) patients had aBismuth type I (n=25, 41.0%) or II (n=36, 59.0%) lesion. The incidence ofR0 resection after BDR only was the same as among patients after LHR and RHR (BDR 70.0% vs. BDR+LHR 71.4% vs. BDR+RHR 76.5%, p=0.891). In contrast, severe complications were more likely after LHR and RHR than BDR only (BDR 21.4% vs. BDR+LHR 60.0% and BDR+RHR 50.0%, p=0.041). Overall (median: BDR 20.9 vs. BDR+LHR 23.2 and BDR+RHR 25.0 months, p=0.213) and recurrence-free (median: BDR 13.4 vs. BDR+LHR 15.3 and BDR+RHR 25.0, p= 0.109) survivalwere comparable. On multivariable analysis, while CA19-9>37.0U/ml (Ref. CA19-9=37.0U/ml, HR 3.2, 95% CI 1.1-9.4, p=0.035) and AJCC T3-T4 disease (Ref. T1-T2, HR 4.6, 95% CI 1.5-13.7, p=0.007) were associated with long-term survival, surgical approach was not (BDR+LHR: HR 1.0, 95% CI 0.5-2.2, p=0.937; BDR+RHR: HR 0.6, 95% CI 0.3-1.3, p=0.197).CONCLUSION: R0 resection, overall survival, and recurrence-free survival were comparableamong well-selectedpatients who had BDR versus BDR+HR for Bismuth type I and II HCCA.

View details for DOI 10.1007/s11605-021-05049-3

View details for PubMedID 34131864